logo
Morgan Stanley Sticks to Its Buy Rating for JAPAN POST HOLDINGS Co (JPHLF)

Morgan Stanley Sticks to Its Buy Rating for JAPAN POST HOLDINGS Co (JPHLF)

Morgan Stanley analyst Takuya Osaka maintained a Buy rating on JAPAN POST HOLDINGS Co (JPHLF – Research Report) yesterday and set a price target of Yen1,720.00.
Confident Investing Starts Here:
According to TipRanks, Osaka is a 5-star analyst with an average return of 122.2% and a 63.16% success rate. Osaka covers the Industrials sector, focusing on stocks such as Keisei Electric Railway Co, Kamigumi Co, and SG Holdings Co.
The word on The Street in general, suggests a Hold analyst consensus rating for JAPAN POST HOLDINGS Co with a $11.11 average price target.
The company has a one-year high of $13.01 and a one-year low of $7.77. Currently, JAPAN POST HOLDINGS Co has an average volume of 1,364.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Daiichi Sankyo Company (DSKYF) Receives a Buy from Bernstein
Daiichi Sankyo Company (DSKYF) Receives a Buy from Bernstein

Business Insider

time2 hours ago

  • Business Insider

Daiichi Sankyo Company (DSKYF) Receives a Buy from Bernstein

Bernstein analyst Miki Sogi maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) yesterday and set a price target of Yen6,400.00. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Sogi is an analyst with an average return of -1.9% and a 45.45% success rate. Sogi covers the Healthcare sector, focusing on stocks such as Daiichi Sankyo Company, Astellas Pharma, and Chugai Pharmaceutical Co. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Daiichi Sankyo Company with a $40.43 average price target. The company has a one-year high of $44.64 and a one-year low of $20.15. Currently, Daiichi Sankyo Company has an average volume of 76.67K.

Morgan Stanley: Nvidia stands out as a unique investment case
Morgan Stanley: Nvidia stands out as a unique investment case

Yahoo

time2 hours ago

  • Yahoo

Morgan Stanley: Nvidia stands out as a unique investment case

-- Morgan Stanley reiterated its Overweight rating on Nvidia (NASDAQ:NVDA), calling it a "unique opportunity" in the semiconductor space and maintaining it as the firm's top pick despite broader concerns about sector headwinds. 'This still seems like a unique opportunity to us,' Morgan Stanley analysts wrote in a note. 'The largest market cap semiconductor company in the world is making a strong case that business will accelerate from here, while there is still significant anxiety—almost consensus—that conditions will decelerate.' Nvidia's most recent results impressed across multiple fronts. 'Gross margins ahead, revenues ex-China strong, networking recovering, positive commentary on the supply chain ramp on racks,' the analysts stated. While there was limited forward guidance on the second half of 2024 or calendar year 2026, Morgan Stanley attributed that restraint to geopolitical sensitivity around China. 'Our view continues to be that we are materially undershipping demand,' the analysts wrote. A key short-term concern, namely that rack bottlenecks are leading to rising inventory among original design manufacturers (ODMs), is expected to resolve soon. 'That rack bottlenecks are causing inventory to build up at the ODMs… will soon be replaced by tight supply of those Bianca cards as rack bottlenecks are cleared and demand strengthens.' Morgan Stanley's continued conviction in Nvidia comes as part of a broader weekly review of semiconductor names. The firm said it also likes Marvell (NASDAQ:MRVL) 'a bit more given the selloff,' and is looking to 'good numbers' from Broadcom (NASDAQ:AVGO) this week. Related articles Morgan Stanley: Nvidia stands out as a unique investment case BioNTech soars 15% on cancer drug deal with Bristol Myers Campbell Soup beats Q3 estimates, reaffirms guidance

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store